Sodium-glucose cotransporter-2 inhibitors (SGLT2is) were originally approved for treating type 2 diabetes mellitus (T2DM) because they lower blood glucose and HbA1c levels. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.